DK4140491T5 - Fremgangsmåde til syntetisering af RNA'er med 5'-kappe - Google Patents
Fremgangsmåde til syntetisering af RNA'er med 5'-kappe Download PDFInfo
- Publication number
- DK4140491T5 DK4140491T5 DK22190426.1T DK22190426T DK4140491T5 DK 4140491 T5 DK4140491 T5 DK 4140491T5 DK 22190426 T DK22190426 T DK 22190426T DK 4140491 T5 DK4140491 T5 DK 4140491T5
- Authority
- DK
- Denmark
- Prior art keywords
- synthesizing
- capped rnas
- rnas
- capped
- Prior art date
Links
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title 1
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221248P | 2015-09-21 | 2015-09-21 | |
| EP21173278.9A EP3906789B1 (en) | 2015-09-21 | 2016-09-20 | Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK4140491T3 DK4140491T3 (da) | 2023-11-27 |
| DK4140491T5 true DK4140491T5 (da) | 2024-07-22 |
Family
ID=58387109
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
| DK21173278.9T DK3906789T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK22175377.5T DK4104687T5 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| DK22190426.1T DK4140491T5 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
| DK21173142.7T DK3954225T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
| DK21173278.9T DK3906789T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK22175377.5T DK4104687T5 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21173142.7T DK3954225T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US10913768B2 (da) |
| EP (8) | EP3906789B1 (da) |
| JP (4) | JP6814997B2 (da) |
| KR (3) | KR20240095306A (da) |
| CN (8) | CN121085982A (da) |
| AU (5) | AU2016328645C1 (da) |
| CA (2) | CA3218662A1 (da) |
| CY (1) | CY1124306T1 (da) |
| DK (5) | DK3352584T3 (da) |
| ES (5) | ES2968335T3 (da) |
| FI (4) | FI4104687T3 (da) |
| HK (1) | HK1255236A1 (da) |
| HR (1) | HRP20211091T1 (da) |
| HU (5) | HUE055458T2 (da) |
| LT (5) | LT3906789T (da) |
| PL (5) | PL4140491T3 (da) |
| PT (5) | PT3954225T (da) |
| RS (1) | RS62129B1 (da) |
| SI (5) | SI4104687T1 (da) |
| SM (1) | SMT202100396T1 (da) |
| WO (1) | WO2017053297A1 (da) |
Families Citing this family (200)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| PL4140491T3 (pl) | 2015-09-21 | 2024-02-26 | Trilink Biotechnologies, Llc | Sposoby syntezy rna z kapem 5' |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| ES2930643T3 (es) | 2015-11-23 | 2022-12-20 | Univ California | Seguimiento y manipulación de ARN celular a través de la administración nuclear de CRISPR/CAS9 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| CN119351474A (zh) | 2017-02-22 | 2025-01-24 | 克里斯珀医疗股份公司 | 用于基因编辑的组合物和方法 |
| WO2018172556A1 (en) | 2017-03-24 | 2018-09-27 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| SG11201910101SA (en) | 2017-05-08 | 2019-11-28 | Gritstone Oncology Inc | Alphavirus neoantigen vectors |
| EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9 |
| AU2018292104B2 (en) | 2017-06-30 | 2025-03-27 | Codexis, Inc. | T7 RNA polymerase variants |
| US10793841B2 (en) * | 2017-06-30 | 2020-10-06 | Codexis, Inc. | T7 RNA polymerase variants |
| AU2018298422B2 (en) | 2017-07-04 | 2023-04-06 | CureVac SE | Novel nucleic acid molecules |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| BR112020005287A2 (pt) | 2017-09-29 | 2020-09-24 | Intellia Therapeutics, Inc. | composições e métodos para edição de gene ttr e tratar amiloidose attr |
| AR113154A1 (es) | 2017-09-29 | 2020-01-29 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para edición del genoma |
| KR20200143391A (ko) | 2018-03-15 | 2020-12-23 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용 |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| EP4227319B1 (en) | 2018-04-17 | 2025-11-26 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| JP7352581B2 (ja) | 2018-06-28 | 2023-09-28 | キュアバック アールエヌエイ プリンター ゲーエムベーハー | Ｒｎａインビトロ転写用バイオリアクター |
| AU2019394996B2 (en) | 2018-12-06 | 2025-11-06 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| EP3897702A2 (en) | 2018-12-21 | 2021-10-27 | CureVac AG | Rna for malaria vaccines |
| SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
| US20220133908A1 (en) | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| PT3924487T (pt) | 2019-02-11 | 2024-05-31 | Ethris Gmbh | Purificação de arnm por filtração de fluxo tangencial |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| WO2020198697A1 (en) | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
| CA3134544A1 (en) | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof |
| EP3947670A2 (en) | 2019-03-28 | 2022-02-09 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for polypeptide expression |
| WO2020214830A1 (en) * | 2019-04-16 | 2020-10-22 | The Regents Of The University Of California | Protein translational control |
| BR112021021262A2 (pt) * | 2019-04-26 | 2021-12-21 | Etherna Immunotherapies Nv | Formulação de mrna |
| CA3141494A1 (en) * | 2019-05-24 | 2020-12-03 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treatment of hemochromatosis |
| CN114072516B (zh) | 2019-05-30 | 2025-01-14 | 磨石生物公司 | 经修饰的腺病毒 |
| US20220313813A1 (en) | 2019-06-18 | 2022-10-06 | Curevac Ag | Rotavirus mrna vaccine |
| US12214218B2 (en) | 2019-07-31 | 2025-02-04 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
| JP2022544412A (ja) | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | 免疫賦活特性が減少したｒｎａ組み合わせおよび組成物 |
| EP4022068A1 (en) * | 2019-08-29 | 2022-07-06 | Universität Zürich | Minimal messenger rnas and uses thereof |
| BR112022011803A2 (pt) | 2019-12-20 | 2022-08-30 | Curevac Ag | Nanopartículas de lipídio para entrega de ácidos nucleicos |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| IL293571B2 (en) | 2020-02-04 | 2025-01-01 | Curevac Ag | Coronavirus vaccine |
| PL432884A1 (pl) * | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL248416B1 (pl) * | 2020-02-12 | 2025-12-08 | Uniwersytet Warszawski | Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| CN115175916B (zh) * | 2020-02-28 | 2025-02-14 | 国立研究开发法人科学技术振兴机构 | 加帽rna的制造方法 |
| CN113151312B (zh) * | 2020-03-02 | 2022-12-09 | 中国科学院微生物研究所 | 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用 |
| US12351834B2 (en) | 2020-03-03 | 2025-07-08 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| WO2021183564A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| KR20220161316A (ko) | 2020-03-30 | 2022-12-06 | 비온테크 에스이 | Claudin-18.2를 표적화하는 rna 조성물 |
| CN115768437A (zh) * | 2020-04-21 | 2023-03-07 | 磨石生物公司 | 加帽化合物、组合物及其使用方法 |
| CN118490818A (zh) * | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| JP2023524071A (ja) | 2020-05-01 | 2023-06-08 | アークトゥラス・セラピューティクス・インコーポレイテッド | 嚢胞性線維症を治療するための核酸及び方法 |
| CA3171986A1 (en) | 2020-05-19 | 2021-11-25 | Michael Paul Marie Gantier | Oligonucleotides |
| CA3170740A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| JP2023533721A (ja) * | 2020-07-02 | 2023-08-04 | ライフ テクノロジーズ コーポレーション | トリヌクレオチドキャップ類似体、それらの調製、及び使用 |
| CA3170741A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| JP2023541108A (ja) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | マルチエピトープワクチンカセット |
| JP2023537609A (ja) | 2020-08-14 | 2023-09-04 | アークトゥラス・セラピューティクス・インコーポレイテッド | 脂質ナノ粒子を凍結乾燥する方法 |
| CN113234782A (zh) * | 2020-08-20 | 2021-08-10 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
| EP4157344A2 (en) | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| WO2022049093A1 (en) | 2020-09-01 | 2022-03-10 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| CN116368226A (zh) | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| IL302215A (en) * | 2020-10-20 | 2023-06-01 | St Pharm Co Ltd | Oligonucleotide for 5'-capped rna synthesis |
| EP4251323A1 (en) | 2020-11-27 | 2023-10-04 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
| KR20230129432A (ko) | 2020-12-09 | 2023-09-08 | 비온테크 에스이 | Rna 제조 |
| AU2021394998A1 (en) | 2020-12-11 | 2023-06-29 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
| KR20230164648A (ko) | 2020-12-22 | 2023-12-04 | 큐어백 에스이 | SARS-CoV-2 변이체에 대한 RNA 백신 |
| CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| JP2024501022A (ja) | 2020-12-28 | 2024-01-10 | アークトゥルス セラピューティクス， インコーポレイテッド | Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ） |
| EP4087938A2 (en) | 2021-01-27 | 2022-11-16 | CureVac AG | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CA3206549A1 (en) | 2021-01-29 | 2022-08-04 | Frederick G. Vogt | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| EP4294445A1 (en) | 2021-02-19 | 2023-12-27 | Pfizer Inc. | Methods of protecting rna |
| JP2024511206A (ja) | 2021-03-26 | 2024-03-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| US20250345524A1 (en) | 2021-03-31 | 2025-11-13 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
| KR20220140140A (ko) | 2021-04-09 | 2022-10-18 | 한미정밀화학주식회사 | 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도 |
| EP4334446A1 (en) | 2021-05-03 | 2024-03-13 | CureVac SE | Improved nucleic acid sequence for cell type specific expression |
| WO2022235847A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Technologies for early detection of variants of interest |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| IL309055A (en) | 2021-06-22 | 2024-02-01 | Intellia Therapeutics Inc | Methods for IN VIVO gene editing in the liver |
| CN117858885A (zh) | 2021-07-05 | 2024-04-09 | 国立研究开发法人科学技术振兴机构 | 核苷酸类的纯化方法和核苷酸类的纯化装置以及疏水性试剂和疏水性底物 |
| EP4116313A1 (en) | 2021-07-07 | 2023-01-11 | Westfälische Wilhelms-Universität Münster | Cap analog for the 5'-end of eukaryotic messenger rnas |
| KR20240042414A (ko) | 2021-07-29 | 2024-04-02 | 비온테크 에스이 | 흑색종의 치료용 조성물 및 방법 |
| WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
| WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| CN118978560A (zh) | 2021-08-27 | 2024-11-19 | 上海兆维科技发展有限公司 | 一种加帽类似物及其应用 |
| JP2024534871A (ja) * | 2021-08-31 | 2024-09-26 | ハンミ・ファイン・ケミカル・カンパニー・リミテッド | ｍＲＮＡキャップ類似体及びその用途 |
| WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| MX2024002725A (es) | 2021-09-03 | 2024-03-15 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos que comprenden fosfatidilserina. |
| CN113957108B (zh) * | 2021-09-09 | 2025-01-10 | 上海兆维科技发展有限公司 | 一种加帽rna的合成方法以及加帽rna转录反应液 |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| JP2024540978A (ja) | 2021-10-22 | 2024-11-06 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖化合物及び複合体 |
| US20240417418A1 (en) | 2021-10-22 | 2024-12-19 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4401788A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| JP2024543247A (ja) | 2021-10-22 | 2024-11-20 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖化合物及び複合体 |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| JP2024542995A (ja) | 2021-11-03 | 2024-11-19 | インテリア セラピューティクス，インコーポレイテッド | ゲノム編集のためのポリヌクレオチド、組成物、及び方法 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20230083197A (ko) | 2021-12-01 | 2023-06-09 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| WO2023115495A1 (zh) * | 2021-12-23 | 2023-06-29 | 北京毅新博创生物科技有限公司 | 质谱法检测mRNA加帽效率的方法 |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| KR20230123318A (ko) | 2022-02-16 | 2023-08-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| GB2615784A (en) | 2022-02-18 | 2023-08-23 | Phion Therapeutics Ltd | mRNA vaccine |
| CA3206012A1 (en) | 2022-02-28 | 2023-08-28 | Guangzhou Henovcom Bioscience Co., Ltd. | Compounds for rna capping and uses thereof |
| CN115260264B (zh) | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| WO2023167880A2 (en) * | 2022-03-01 | 2023-09-07 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| US12037616B2 (en) | 2022-03-01 | 2024-07-16 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions |
| WO2023180904A1 (en) | 2022-03-21 | 2023-09-28 | Crispr Therapeutics Ag | Methods and compositions for treating lipoprotein-related diseases |
| WO2023191342A1 (ko) | 2022-03-31 | 2023-10-05 | 한미정밀화학 주식회사 | mRNA 캡 유사체 및 이의 용도 |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| GB2618818A (en) | 2022-05-18 | 2023-11-22 | Phion Therapeutics Ltd | Vaccine |
| CN119212720A (zh) | 2022-05-25 | 2024-12-27 | 库瑞瓦格欧洲股份公司 | 编码大肠杆菌FimH抗原性多肽的基于核酸的疫苗 |
| JP2025518221A (ja) | 2022-05-30 | 2025-06-12 | ビオンテック・ソシエタス・エウロパエア | 核酸の送達のための複合体 |
| WO2023235422A2 (en) * | 2022-05-31 | 2023-12-07 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2023235362A1 (en) * | 2022-05-31 | 2023-12-07 | Nutcracker Therapeutics, Inc. | Rna cap analogs and methods of use |
| AU2023295529A1 (en) | 2022-06-16 | 2024-12-12 | Intellia Therapeutics, Inc. | Methods and compositions for genetically modifying a cell |
| WO2023246860A1 (zh) * | 2022-06-22 | 2023-12-28 | 江苏申基生物科技有限公司 | 一种起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115109110B (zh) * | 2022-06-22 | 2024-07-12 | 江苏申基生物科技有限公司 | 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115057903B (zh) * | 2022-06-22 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN114853836B (zh) * | 2022-06-24 | 2024-05-14 | 江苏申基生物科技有限公司 | 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN114941018B (zh) * | 2022-06-28 | 2023-09-22 | 翌圣生物科技(上海)股份有限公司 | cap1帽类似物的合成方法 |
| KR20240010238A (ko) | 2022-07-15 | 2024-01-23 | 한미정밀화학주식회사 | 캡 유사체 및 이의 용도 |
| US11898186B1 (en) | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
| CN115925773A (zh) * | 2022-08-23 | 2023-04-07 | 合肥华纳生物医药科技有限公司 | 一种新型信使核糖核酸帽类似物 |
| JP2025527722A (ja) * | 2022-08-26 | 2025-08-22 | トライリンク バイオテクノロジーズ， エルエルシー | 高度に精製された５’キャップ付きオリゴヌクレオチドを作製するための効率的な方法 |
| CN117645642A (zh) * | 2022-09-05 | 2024-03-05 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| JP2025531877A (ja) | 2022-09-09 | 2025-09-25 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| EP4572796A1 (en) | 2022-09-26 | 2025-06-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
| KR20250075664A (ko) | 2022-09-26 | 2025-05-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 인플루엔자 바이러스 백신 |
| CN120092014A (zh) | 2022-10-04 | 2025-06-03 | 生物技术欧洲股份公司 | Rna构建体和其用途 |
| JP2025534447A (ja) | 2022-10-06 | 2025-10-15 | バイオエヌテック エスエー | クローディン１８．２を標的とするｒｎａ組成物 |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| EP4605010A1 (en) | 2022-10-21 | 2025-08-27 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
| CN116143855B (zh) * | 2022-11-08 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用 |
| EP4638736A1 (en) | 2022-12-23 | 2025-10-29 | Intellia Therapeutics, Inc. | Systems and methods for genomic editing |
| EP4397669A1 (en) | 2023-01-06 | 2024-07-10 | Westfälische Wilhelms-Universität Münster | Photocaged cap analogs for the 5'-end of rnas |
| TW202444408A (zh) | 2023-01-20 | 2024-11-16 | 瑞典商阿斯特捷利康公司 | 疫苗 |
| IL322194A (en) | 2023-01-20 | 2025-09-01 | Astrazeneca Ab | Nucleic acid molecules |
| EP4658664A1 (en) | 2023-01-31 | 2025-12-10 | CureVac SE | Cap analogs with 5'-terminal acyclic guanosine derivative |
| EP4658239A1 (en) | 2023-02-03 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| KR20250157528A (ko) | 2023-03-03 | 2025-11-04 | 나티아스 인크. | 폴리인산화 뉴클레오시드, 폴리인산화 뉴클레오시드의 합성에 사용되는 인산부 활성화 뉴클레오티드 및 그 합성 방법, 및 인산부 활성화 뉴클레오티드를 사용한 폴리인산화 뉴클레오시드의 합성 방법 |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| TW202444914A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 抑制子融合蛋白系統 |
| AU2024248139A1 (en) | 2023-03-29 | 2025-09-25 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| CN118726510A (zh) * | 2023-03-31 | 2024-10-01 | 苏州近岸蛋白质科技股份有限公司 | 一管法酶促合成加帽mRNA的方法 |
| CN118772219B (zh) * | 2023-04-04 | 2025-12-02 | 深圳瑞吉生物科技有限公司 | 一种用于核酸的5’端加帽的含卤化合物及其应用 |
| CN121001738A (zh) | 2023-04-27 | 2025-11-21 | 葛兰素史克生物有限公司 | 流感病毒疫苗 |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| WO2024235451A1 (en) | 2023-05-16 | 2024-11-21 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| WO2024245907A1 (en) | 2023-05-26 | 2024-12-05 | CureVac SE | Cancer antigens |
| WO2024260570A1 (en) | 2023-06-23 | 2024-12-26 | CureVac SE | Nucleic acid encoded antibodies |
| WO2025022290A1 (en) | 2023-07-21 | 2025-01-30 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| WO2025027060A1 (en) | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| TW202519509A (zh) | 2023-08-01 | 2025-05-16 | 德商拜恩技術股份公司 | 可離子化硫脂質及其用途 |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| WO2025036992A1 (en) | 2023-08-16 | 2025-02-20 | CureVac SE | Rna conjugates |
| WO2025054401A2 (en) * | 2023-09-06 | 2025-03-13 | Trilink Biotechnologies, Llc | Cap analogs and methods of use thereof |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025071359A1 (ko) | 2023-09-27 | 2025-04-03 | 한미정밀화학 주식회사 | mRNA 캡 유사체 및 이의 용도 |
| WO2025088088A1 (en) | 2023-10-27 | 2025-05-01 | CureVac SE | Rna composition for improving cell therapy |
| WO2025101994A2 (en) | 2023-11-10 | 2025-05-15 | Intellia Therapeutics, Inc. | Compositions, methods, and systems for genomic editing |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| TW202525287A (zh) | 2023-12-21 | 2025-07-01 | 德商拜恩技術運輸科技有限責任公司 | 可離子化脂質 |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025147660A2 (en) | 2024-01-04 | 2025-07-10 | Trilink Biotechnologies, Llc | Modified rna for increasing protein expression |
| US20250269059A1 (en) | 2024-02-27 | 2025-08-28 | Crispr Therapeutics Ag | Rt editing compositions and methods |
| WO2025186726A1 (en) | 2024-03-05 | 2025-09-12 | Crispr Therapeutics Ag | Modulating expression of agt (angiotensinogen) gene |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| WO2025208142A2 (en) | 2024-03-29 | 2025-10-02 | New England Biolabs, Inc. | Compositions, kits, and methods for in vitro transcription |
| EP4650358A2 (en) * | 2024-04-26 | 2025-11-19 | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Ribose-modified cap analog and use thereof |
| WO2025240940A1 (en) | 2024-05-17 | 2025-11-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of apolipoprotein c3 |
| WO2025242815A1 (en) | 2024-05-23 | 2025-11-27 | CureVac SE | Immunotherapy of squamous cell carcinoma |
| CN120608113A (zh) * | 2024-11-29 | 2025-09-09 | 上海蓝鹊生物医药有限公司 | 一种合成Cap2结构5'-加帽RNA的组合和方法 |
| CN119306779A (zh) * | 2024-12-13 | 2025-01-14 | 上海科泽永欣生物科技有限公司 | 一种含r构型的起始加帽寡核苷酸引物及其合成方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1997A (en) | 1841-03-03 | Improvement in the mode of rendering fabrics water-proof | ||
| EP0081099A3 (en) | 1981-12-04 | 1983-08-10 | Sloan-Kettering Institute For Cancer Research | Capped oligonucleotide anti-viral agents |
| DE3148702C2 (de) * | 1981-12-09 | 1985-05-15 | Dieter Gräßlin Feinwerktechnik, 7742 St Georgen | Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte |
| US5837852A (en) | 1993-10-14 | 1998-11-17 | Bristol-Myers Squibb Company | Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease |
| US6965041B1 (en) | 1999-03-24 | 2005-11-15 | The United States Of America As Represented By The Department Of Health And Human Services | N-acylphosphoramidites and their use in oligonucleotide synthesis |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7629325B2 (en) * | 2004-10-11 | 2009-12-08 | Technion Research & Development Foundation Ltd. | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy |
| EP1819365B1 (en) | 2004-12-09 | 2014-07-02 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
| ATE502122T1 (de) | 2006-06-01 | 2011-04-15 | Trilink Biotechnologies | Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| US20080248469A1 (en) | 2006-08-16 | 2008-10-09 | Applera Corporation | Methods for Identifying Nucleotides of Interest in Target Polynucleotides |
| CN107501370B (zh) | 2007-06-19 | 2021-06-18 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗-反向硫代磷酸类似物的合成和用途 |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US9067964B2 (en) | 2008-12-18 | 2015-06-30 | Oligomer Sciences Ab | Complex and method for enhancing nuclear delivery |
| US8557972B2 (en) | 2009-12-21 | 2013-10-15 | University Of Washington Through Its Center For Commercialization | Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA |
| WO2011157617A1 (en) | 2010-06-17 | 2011-12-22 | Febit Holding Gmbh | Complex set of mirna libraries |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| HK1206601A1 (en) * | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| CA2903488A1 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger rna |
| JP6148592B2 (ja) | 2013-10-15 | 2017-06-14 | ヤマハ発動機株式会社 | 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両 |
| EP3904366A1 (en) | 2014-12-16 | 2021-11-03 | Novartis AG | End capped nucleic acid molecules |
| PL4140491T3 (pl) | 2015-09-21 | 2024-02-26 | Trilink Biotechnologies, Llc | Sposoby syntezy rna z kapem 5' |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| KR20200143391A (ko) | 2018-03-15 | 2020-12-23 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용 |
| US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
| PL248416B1 (pl) | 2020-02-12 | 2025-12-08 | Uniwersytet Warszawski | Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL432884A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| JP2023533721A (ja) | 2020-07-02 | 2023-08-04 | ライフ テクノロジーズ コーポレーション | トリヌクレオチドキャップ類似体、それらの調製、及び使用 |
| IL302215A (en) | 2020-10-20 | 2023-06-01 | St Pharm Co Ltd | Oligonucleotide for 5'-capped rna synthesis |
-
2016
- 2016-09-20 PL PL22190426.1T patent/PL4140491T3/pl unknown
- 2016-09-20 EP EP21173278.9A patent/EP3906789B1/en active Active
- 2016-09-20 DK DK16849423.5T patent/DK3352584T3/da active
- 2016-09-20 LT LTEP21173278.9T patent/LT3906789T/lt unknown
- 2016-09-20 FI FIEP22175377.5T patent/FI4104687T3/fi active
- 2016-09-20 KR KR1020247017688A patent/KR20240095306A/ko active Pending
- 2016-09-20 US US15/761,957 patent/US10913768B2/en active Active
- 2016-09-20 EP EP16849423.5A patent/EP3352584B1/en active Active
- 2016-09-20 CN CN202511246658.5A patent/CN121085982A/zh active Pending
- 2016-09-20 CN CN202310734863.0A patent/CN116751827B/zh active Active
- 2016-09-20 PT PT211731427T patent/PT3954225T/pt unknown
- 2016-09-20 CN CN201680067458.6A patent/CN108366604A/zh active Pending
- 2016-09-20 ES ES21173278T patent/ES2968335T3/es active Active
- 2016-09-20 ES ES16849423T patent/ES2879686T3/es active Active
- 2016-09-20 PL PL16849423T patent/PL3352584T3/pl unknown
- 2016-09-20 AU AU2016328645A patent/AU2016328645C1/en active Active
- 2016-09-20 LT LTEP16849423.5T patent/LT3352584T/lt unknown
- 2016-09-20 SI SI201631802T patent/SI4104687T1/sl unknown
- 2016-09-20 SI SI201631248T patent/SI3352584T1/sl unknown
- 2016-09-20 CN CN202511246578.XA patent/CN121064267A/zh active Pending
- 2016-09-20 LT LTEP21173142.7T patent/LT3954225T/lt unknown
- 2016-09-20 EP EP21173142.7A patent/EP3954225B1/en active Active
- 2016-09-20 LT LTEP22175377.5T patent/LT4104687T/lt unknown
- 2016-09-20 PL PL22175377.5T patent/PL4104687T3/pl unknown
- 2016-09-20 HU HUE16849423A patent/HUE055458T2/hu unknown
- 2016-09-20 LT LTEP22190426.1T patent/LT4140491T/lt unknown
- 2016-09-20 SM SM20210396T patent/SMT202100396T1/it unknown
- 2016-09-20 CN CN202511246712.6A patent/CN120842296A/zh active Pending
- 2016-09-20 HU HUE22175377A patent/HUE065704T2/hu unknown
- 2016-09-20 EP EP24186081.6A patent/EP4424835A3/en active Pending
- 2016-09-20 PT PT211732789T patent/PT3906789T/pt unknown
- 2016-09-20 HU HUE22190426A patent/HUE064227T2/hu unknown
- 2016-09-20 EP EP21173131.0A patent/EP3954224A1/en active Pending
- 2016-09-20 HU HUE21173142A patent/HUE065331T2/hu unknown
- 2016-09-20 DK DK21173278.9T patent/DK3906789T5/da active
- 2016-09-20 HU HUE21173278A patent/HUE065203T2/hu unknown
- 2016-09-20 PT PT221904261T patent/PT4140491T/pt unknown
- 2016-09-20 FI FIEP21173278.9T patent/FI3906789T3/fi active
- 2016-09-20 CN CN202311200887.4A patent/CN117025590A/zh active Pending
- 2016-09-20 CA CA3218662A patent/CA3218662A1/en active Pending
- 2016-09-20 EP EP22190426.1A patent/EP4140491B1/en active Active
- 2016-09-20 ES ES22190426T patent/ES2964690T3/es active Active
- 2016-09-20 KR KR1020187010893A patent/KR102500198B1/ko active Active
- 2016-09-20 ES ES22175377T patent/ES2972098T3/es active Active
- 2016-09-20 HR HRP20211091TT patent/HRP20211091T1/hr unknown
- 2016-09-20 FI FIEP21173142.7T patent/FI3954225T3/fi active
- 2016-09-20 RS RS20210857A patent/RS62129B1/sr unknown
- 2016-09-20 EP EP23192203.0A patent/EP4276189A3/en active Pending
- 2016-09-20 CN CN202110537080.4A patent/CN113584020A/zh active Pending
- 2016-09-20 EP EP22175377.5A patent/EP4104687B1/en active Active
- 2016-09-20 KR KR1020237004950A patent/KR102670937B1/ko active Active
- 2016-09-20 DK DK22175377.5T patent/DK4104687T5/da active
- 2016-09-20 JP JP2018515136A patent/JP6814997B2/ja active Active
- 2016-09-20 DK DK22190426.1T patent/DK4140491T5/da active
- 2016-09-20 PT PT221753775T patent/PT4104687T/pt unknown
- 2016-09-20 PT PT168494235T patent/PT3352584T/pt unknown
- 2016-09-20 DK DK21173142.7T patent/DK3954225T5/da active
- 2016-09-20 SI SI201631772T patent/SI3906789T1/sl unknown
- 2016-09-20 PL PL21173142.7T patent/PL3954225T3/pl unknown
- 2016-09-20 CA CA2999274A patent/CA2999274C/en active Active
- 2016-09-20 FI FIEP22190426.1T patent/FI4140491T3/fi active
- 2016-09-20 ES ES21173142T patent/ES2968391T3/es active Active
- 2016-09-20 PL PL21173278.9T patent/PL3906789T3/pl unknown
- 2016-09-20 WO PCT/US2016/052670 patent/WO2017053297A1/en not_active Ceased
- 2016-09-20 SI SI201631773T patent/SI3954225T1/sl unknown
- 2016-09-20 HK HK18114366.7A patent/HK1255236A1/zh unknown
- 2016-09-20 SI SI201631757T patent/SI4140491T1/sl unknown
- 2016-09-20 CN CN202211046591.7A patent/CN116590285A/zh active Pending
-
2018
- 2018-12-26 US US16/232,435 patent/US10519189B2/en active Active
-
2019
- 2019-04-01 US US16/371,317 patent/US10494399B2/en active Active
-
2020
- 2020-11-06 US US17/091,422 patent/US11878991B2/en active Active
- 2020-12-10 JP JP2020204713A patent/JP7082174B2/ja active Active
-
2021
- 2021-07-07 CY CY20211100612T patent/CY1124306T1/el unknown
- 2021-07-19 AU AU2021206780A patent/AU2021206780C1/en active Active
- 2021-08-02 US US17/392,170 patent/US11414453B2/en active Active
-
2022
- 2022-04-22 JP JP2022070512A patent/JP7594563B2/ja active Active
- 2022-05-26 US US17/804,192 patent/US11578095B2/en active Active
-
2023
- 2023-03-29 AU AU2023201915A patent/AU2023201915B2/en active Active
- 2023-09-13 AU AU2023229522A patent/AU2023229522B2/en active Active
- 2023-09-14 US US18/467,224 patent/US12258369B2/en active Active
-
2024
- 2024-01-09 US US18/408,431 patent/US12103944B2/en active Active
- 2024-06-26 JP JP2024102548A patent/JP2024150459A/ja active Pending
-
2025
- 2025-01-17 US US19/028,051 patent/US20250171489A1/en active Pending
- 2025-05-13 AU AU2025203425A patent/AU2025203425A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4140491T3 (da) | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe | |
| DK3585892T3 (da) | Fremgangsmåder til oprensning af messenger-rna | |
| DK3585891T3 (da) | Fremgangsmåder til oprensning af messenger-rna | |
| DK3337902T3 (da) | 3'-utr-sekvenser til stabilisering af rna | |
| DK3294885T3 (da) | Fremgangsmåde til at fremstille rna | |
| DK3636742T3 (da) | Fremgangsmåder til oprensning af messenger-rna | |
| DK3445850T3 (da) | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna | |
| DK3319622T3 (da) | Fremgangsmåde til fremstilling af rna-molekylesammensætninger | |
| DK3292134T3 (da) | Metode til dyrkning af akkermansia | |
| DK3728585T3 (da) | Hidtil ukendte fremgangsmåder til fremstilling af oligonukleotider | |
| DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
| DK3607068T3 (da) | RNA-interferensmedieret inhibering af TMPRSS6 | |
| EP3323147A4 (en) | METHOD FOR SELECTIVE EPITAXIA | |
| DK3374333T3 (da) | Fremgangsmåde til fremstilling af urea-gødningsmiddel | |
| DK3191498T3 (da) | Fremgangsmåde til fremstilling af 2'-o-fucosyllactose | |
| DK3347481T3 (da) | Fremgangsmåde til oprensning af biomassehydrolysat | |
| DK3328816T3 (da) | Fremgangsmåde til genvinding af fosfor | |
| DK3386947T3 (da) | Fremgangsmåde til fremstilling af n-retinoylaminoalkansulfonsyre | |
| EP3389363A4 (en) | PROCEDURE FOR IN-VITRO | |
| DK3356541T3 (da) | Fremgangsmåde til fremstilling af l-methionin | |
| DK3356540T3 (da) | Fremgangsmåde til fremstilling af l-methionin | |
| DK3652187T3 (da) | Forbedret fremgangsmåde til fremstilling af imetelstat | |
| DK3381914T3 (da) | Fremgangsmåde til oprensning af benzopyranderivat, krystallinsk form deraf og fremgangsmåde til fremstilling af den krystallinske form | |
| DK3371197T3 (da) | Fremgangsmåde til selektiv syntese af trialkoxysilaner | |
| DK3294725T3 (da) | Fremgangsmåde til fremstilling af 4-aminopyridaziner |